Galapagos (NASDAQ:GLPG), a global biotechnology company, announced today that its Chief Financial Officer (CFO) and Chief Operating Officer (COO), Thad Huston, will be departing from the company effective August 1, 2025.
According to the company's statement, Mr. Huston has decided to leave Galapagos and return to the United States for personal and professional reasons.
He joined the biotechnology firm in 2023, coming from Kite Pharma, with the specific aim of supporting Galapagos' strategic shift towards becoming a cell therapy company.
Galapagos anticipates announcing Mr. Huston's successor in the coming months.
Meanwhile, this announcement comes as Galapagos continues its focus on developing and commercializing innovative cell therapies.
The company's decentralized platform aims to deliver rapid and efficient CAR-T therapy to patients.